{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "treatment-of", "type": "definition", "offset": [10, 22]}, {"key": "additional-indication", "type": "definition", "offset": [26, 47]}], "samples": [{"hash": "7T5uPuM9hsh", "uri": "/contracts/7T5uPuM9hsh#additional-field", "label": "Strategic Collaboration and License Agreement (Codexis, Inc.)", "score": 31.3490759754, "published": true}, {"hash": "8Eg0myGinIQ", "uri": "https://ir.codexis.com/sec-filings/quarterly-reports/content/0001200375-20-000020/0001200375-20-000020.pdf", "label": "ir.codexis.com", "score": 8.4099931554, "published": false}, {"hash": "3OmdGBmiDeA", "uri": "https://ir.codexis.com/static-files/f5e55691-62ad-4ef6-8749-af4ab9436e07", "label": "ir.codexis.com", "score": 8.1745379877, "published": false}], "snippet": "means the Treatment of an Additional Indication in humans.", "size": 3, "hash": "f2c9859cf76221361fcb69661894f299", "id": 1}, {"snippet_links": [{"key": "therapeutic-area", "type": "definition", "offset": [74, 90]}, {"key": "rnai-compound", "type": "definition", "offset": [141, 154]}], "samples": [{"hash": "jEVVmoQjUH3", "uri": "/contracts/jEVVmoQjUH3#additional-field", "label": "License and Collaboration Agreement (Arrowhead Research Corp)", "score": 22.9657768652, "published": true}, {"hash": "8Sk3Ami7WJK", "uri": "/contracts/8Sk3Ami7WJK#additional-field", "label": "License and Collaboration Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "2E59iC5c6EH", "uri": "/contracts/2E59iC5c6EH#additional-field", "label": "License and Collaboration Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 21.0, "published": true}], "snippet": "means the treatment or prophylaxis of all Indications in any Supplemental Therapeutic Area, where such treatment or prophylaxis comprises an RNAi Compound complementary to, and functional in mediating the RNAi of, a Target known or believed to be primarily implicated in such Supplemental Therapeutic Area.", "size": 3, "hash": "d849c81e630230aefe75cb7d5a4825c4", "id": 2}, {"snippet_links": [{"key": "topical-formulation", "type": "definition", "offset": [10, 29]}, {"key": "licensed-compound", "type": "definition", "offset": [36, 53]}, {"key": "treatment-of", "type": "definition", "offset": [72, 84]}], "samples": [{"hash": "aRiAjyhHfle", "uri": "/contracts/aRiAjyhHfle#additional-field", "label": "Exclusive Option and License Agreement (Arcutis Biotherapeutics, Inc.)", "score": 31.0123203285, "published": true}, {"hash": "3cC1wgENhSP", "uri": "/contracts/3cC1wgENhSP#additional-field", "label": "Exclusive Option and License Agreement (Arcutis Biotherapeutics, Inc.)", "score": 30.8617385352, "published": true}], "snippet": "means non-topical formulation\u2019s) of Licensed Compound indicated for the treatment of psoriasis, vitiligo, atopic dermatitis, alopecia areata, and. or hidradenitis suppurativa.", "size": 2, "hash": "4de8e5465d4636678c402d80272a5b8a", "id": 3}, {"snippet_links": [{"key": "treatment-of", "type": "definition", "offset": [10, 22]}], "samples": [{"hash": "8wg5WRzmxEL", "uri": "/contracts/8wg5WRzmxEL#additional-field", "label": "Licence and Distribution Agreement (Amarin Corp Plc\\uk)", "score": 20.0, "published": true}, {"hash": "1GVH8Tsbl4O", "uri": "/contracts/1GVH8Tsbl4O#additional-field", "label": "Licence and Distribution Agreement (Amarin Corp Plc\\uk)", "score": 20.0, "published": true}], "snippet": "means the treatment of depression;", "size": 2, "hash": "1fa0f0b6b6329616337afe4f9f9b601e", "id": 4}, {"snippet_links": [{"key": "applications-for", "type": "clause", "offset": [20, 36]}, {"key": "but-excluding", "type": "clause", "offset": [107, 120]}], "samples": [{"hash": "kxkjnbtSwn7", "uri": "/contracts/kxkjnbtSwn7#additional-field", "label": "Technologies License, Development, Consulting and Collaboration Agreement (Lifef X Inc)", "score": 18.0, "published": true}], "snippet": "means all Animation Applications for use in any ---------------- field other than the Entertainment Field, but excluding professional medical, engineering and scientific applications.", "size": 1, "hash": "edf92dfb40b002225a19b2539d67270f", "id": 5}, {"snippet_links": [{"key": "scope-of-this-agreement", "type": "clause", "offset": [35, 58]}, {"key": "in-accordance-with", "type": "definition", "offset": [59, 77]}, {"key": "section-43", "type": "clause", "offset": [78, 89]}], "samples": [{"hash": "8VehsTN9FKn", "uri": "/contracts/8VehsTN9FKn#additional-field", "label": "License Agreement (Axonics Modulation Technologies, Inc.)", "score": 29.6543463381, "published": true}], "snippet": "means a field that is added to the scope of this Agreement in accordance with Section 4.3.", "size": 1, "hash": "78c797ffd00f2c1bf6d58d8ced7cd496", "id": 6}, {"snippet_links": [{"key": "therapeutic-area", "type": "definition", "offset": [84, 100]}], "samples": [{"hash": "absHN1ffB62", "uri": "/contracts/absHN1ffB62#additional-field", "label": "License and Collaboration Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 21.0, "published": true}], "snippet": "means the treatment, palliation or prophylaxis of all Indications in a Supplemental Therapeutic Area.", "size": 1, "hash": "c145660d4fddf67de985e59c88bfc24f", "id": 7}, {"snippet_links": [{"key": "primary-field", "type": "definition", "offset": [116, 129]}, {"key": "oncology-field", "type": "definition", "offset": [137, 151]}], "samples": [{"hash": "jxF7HJGv1LW", "uri": "/contracts/jxF7HJGv1LW#additional-field", "label": "Collaborative Research and License Agreement (Celgene Corp /De/)", "score": 18.0, "published": true}], "snippet": "means the treatment, prevention and diagnosis of a disease or disorder, other than a disease or disorder within the Primary Field or the Oncology Field.", "size": 1, "hash": "c69aa22dc1515158fd73501b5b467346", "id": 8}, {"snippet_links": [{"key": "the-field", "type": "definition", "offset": [6, 15]}, {"key": "comprised-of", "type": "clause", "offset": [16, 28]}, {"key": "in-accordance-with", "type": "definition", "offset": [99, 117]}, {"key": "section-38", "type": "clause", "offset": [118, 129]}], "samples": [{"hash": "5DzjJXZs06U", "uri": "/contracts/5DzjJXZs06U#additional-field", "label": "Exclusive License Agreement (Arqule Inc)", "score": 21.0, "published": true}], "snippet": "means the field comprised of Indications designated by the JSC as included in the Additional Field in accordance with Section 3.8 hereof.", "size": 1, "hash": "379637cd09f5414b47dddeefbee7e545", "id": 9}, {"snippet_links": [{"key": "scope-of-the", "type": "clause", "offset": [10, 22]}, {"key": "pharmaceutical-products", "type": "definition", "offset": [30, 53]}, {"key": "psychiatric-indications", "type": "clause", "offset": [96, 119]}, {"key": "field-of-use", "type": "definition", "offset": [153, 165]}, {"key": "covered-by", "type": "definition", "offset": [192, 202]}, {"key": "licensed-patents", "type": "definition", "offset": [207, 223]}], "samples": [{"hash": "6BnW5XPDyBv", "uri": "/contracts/6BnW5XPDyBv#additional-field", "label": "Licence Agreement (Amarin Corp Plc\\uk)", "score": 20.0, "published": true}], "snippet": "means the scope of the use of pharmaceutical products containing ethyl EPA for neurological and psychiatric indications other than those detailed in the Field of Use and which indications are covered by the Licensed Patents (as after defined);", "size": 1, "hash": "4a846787064f81bf98684ffb2df80ea1", "id": 10}], "next_curs": "Cl0SV2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjkLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIZYWRkaXRpb25hbC1maWVsZCMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"snippet": "means the Treatment of an Additional Indication in humans.", "size": 20, "title": "Additional Field", "id": "additional-field", "examples": ["In the event that the Field Definition Panel determines that Licensee\u2019s Discovery, Development, Commercialization or Manufacturing activities are being conducted in any <strong>Additional Field</strong> in a manner which is prohibited hereunder, Licensee shall, within ten (10) Business Days after such determination by the Field Definition Panel, cease such proscribed activity.", "For each <strong>Additional Field</strong> granted to scPharma exclusively, the Incremental Disposable Units volume established in Exhibit 2.6(a) will be added to the Minimum Volumes.", "Upon Licensee\u2019s payment of the Field Option Fee for each such <strong>Additional Field</strong> pursuant to Section 5.6, the licenses granted to Licensee under Section 2.1(a) shall include such <strong>Additional Field</strong>(s).", "In that event, scPharma will provide Sensile written notice of its intentions and the applicable <strong>Additional Field</strong>.", "The continuation of exclusivity in the Exclusive License shall be subject to Section 2.6. In the event additional exclusive fields are added in accordance with Section 2.7, the License shall be exclusive as agreed by the Parties for such <strong>Additional Field</strong> (defined below), and the definitions of Exclusive Areas and Field of Use shall be deemed to include such, additional exclusive fields.", "Within thirty (30) days of the Licensee\u2019s receipt of this notice, the Licensee shall have the option to accept the <strong>additional field</strong> space and pay the increased fee to the Town or provide written notice to the Town that the Licensee elects not to use the <strong>Additional Field</strong> Space.", "If HHT does not provide such Term Sheet to OpGen by the expiration of the Offer Period, OpGen shall be free to offer the <strong>Additional Field</strong> Offer plan to any third party or to develop such plan independently.", "Merck, at its sole discretion, may exercise the Option for each <strong>Additional Field</strong> for a period from the Effective Date until the third (3rd) anniversary from the Effective Date (the \u201cOption Notice Period\u201d).", "Merck may, with respect to such <strong>Additional Field</strong>, exercise the Option during the Option Notice Period by providing a written notice of exercise of such Option (the \u201cOption Exercise Notice\u201d) to \u2587\u2587\u2587\u2587\u2587.", "If Merck notifies \u2587\u2587\u2587\u2587\u2587 that it is exercising the Option with respect to an <strong>Additional Field</strong>, no further Option Maintenance Fees with respect to that <strong>Additional Field</strong> (other than those that were due and owing prior to Merck providing \u2587\u2587\u2587\u2587\u2587 with the Option Exercise Notice) shall be due and owing to \u2587\u2587\u2587\u2587\u2587 for such <strong>Additional Field</strong>."], "related": [["additional-indication", "Additional Indication", "Additional Indication"], ["additional-sdu-study", "Additional SDU Study", "Additional SDU Study"], ["licensed-field", "Licensed Field", "Licensed Field"], ["additional-filing-date", "Additional Filing Date", "Additional Filing Date"], ["licensed-field-of-use", "Licensed Field of Use", "Licensed Field of Use"]], "related_snippets": [], "updated": "2025-07-06T21:58:36+00:00"}, "json": true, "cursor": ""}}